Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus has licensed its over-the-counter product Zegerid, indicated for heartburn, to Schering-Plough in order to commercialize the drug in the US and Canada.
Subscribe to our email newsletter
Schering-Plough will be responsible for the development, manufacturing and commercialization of over-the-counter (OTC) products with the lower dosage strength of 20 mg for heartburn-related indications.
Santarus will continue to manufacture, promote and sell Zegerid products in both 40mg and 20mg dosage strengths for their approved prescription indications in the US prescription market for proton pump inhibitor products.
Under the terms of the agreement, Santarus will receive a $15 million upfront license fee payable following the effective date of the agreement and may receive up to an additional $65 million in milestone payments. Santarus will also receive a royalty on net sales of any Zegerid OTC products
“We believe the development of Zegerid products appropriate for the OTC market will provide a healthcare benefit to consumers and may have a positive future impact on overall awareness of our prescription Zegerid products, the significant majority of which are currently prescribed at the higher 40mg dosage strength,” said Gerald Proehl, president and CEO of Santarus.